Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease?

The Lancet Global Health

Volumn 2, Issue 12, 2014, Pages e686-

  Almansa, Raquel ^a   Eiros, Jose Maria ^a   Fedson, David ^b   Bermejo Martin, Jesus F ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b Sergy Haut   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERIMMUNE GLOBULIN; ANTIVIRUS AGENT;

ADJUVANT THERAPY; CONVALESCENCE; EBOLA HEMORRHAGIC FEVER; LETTER; RISK ASSESSMENT; SURVIVOR; VACCINATION; VACCINE PRODUCTION; DRUG REPOSITIONING; HEMORRHAGIC FEVER, EBOLA; HUMAN;

ANTIVIRAL AGENTS; DRUG REPOSITIONING; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84918795472     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(14)70341-9     Document Type: Letter

References (5)

1. Gupta R Rethinking the development of Ebola treatments. Lancet Glob Health 2014, 2:e563-e564.
2. Position paper on collection and use of convalescent plasma or serum as an element in filovirus outbreak response WHO Blood Regulators Network, (accessed Oct 27, 2014). http://www.who.int/bloodproducts/brn/brn_positionpaperconvplasmafiloviruses_finalweb14august2014.pdf.
3. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999, 179(suppl 1):S18-S23.
4. Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 2012, 109:5034-5039.
5. Cohen J Ebola vaccines racing forward at record pace. Science 2014, 345:1228-1229.